An anti-inflammatory diet as treatment for inflammatory bowel disease: a case series report

Barbara C Olendzki, Taryn D Silverstein, Gioia M Persuitte, Yunsheng Ma, Katherine R Baldwin, David Cave, Barbara C Olendzki, Taryn D Silverstein, Gioia M Persuitte, Yunsheng Ma, Katherine R Baldwin, David Cave

Abstract

Background: The Anti-Inflammatory Diet (IBD-AID) is a nutritional regimen for inflammatory bowel disease (IBD) that restricts the intake of certain carbohydrates, includes the ingestion of pre- and probiotic foods, and modifies dietary fatty acids to demonstrate the potential of an adjunct dietary therapy for the treatment of IBD.

Methods: Forty patients with IBD were consecutively offered the IBD-AID to help treat their disease, and were retrospectively reviewed. Medical records of 11 of those patients underwent further review to determine changes in the Harvey Bradshaw Index (HBI) or Modified Truelove and Witts Severity Index (MTLWSI), before and after the diet.

Results: Of the 40 patients with IBD, 13 patients chose not to attempt the diet (33%). Twenty-four patients had either a good or very good response after reaching compliance (60%), and 3 patients' results were mixed (7%). Of those 11 adult patients who underwent further medical record review, 8 with CD, and 3 with UC, the age range was 19-70 years, and they followed the diet for 4 or more weeks. After following the IBD-AID, all (100%) patients were able to discontinue at least one of their prior IBD medications, and all patients had symptom reduction including bowel frequency. The mean baseline HBI was 11 (range 1-20), and the mean follow-up score was 1.5 (range 0-3). The mean baseline MTLWSI was 7 (range 6-8), and the mean follow-up score was 0. The average decrease in the HBI was 9.5 and the average decrease in the MTLWSI was 7.

Conclusion: This case series indicates potential for the IBD-AID as an adjunct dietary therapy for the treatment of IBD. A randomized clinical trial is warranted.

References

    1. Day AS, Ledder O, Leach ST, Lemberg DA. Crohn’s and colitis in children and adolescents. World J Gastroenterol. 2012;18:5862–5869. doi: 10.3748/wjg.v18.i41.5862.
    1. Brown AC, Rampertab SD, Mullin GE. Existing dietary guidelines for Crohn’s disease and ulcerative colitis. Expert Rev Gastroenterol Hepatol. 2011;5:411–425. doi: 10.1586/egh.11.29.
    1. Balfour Sartor R. Probiotics for Gastrointestinal Diseases. UpToDate 2013.Location: 95 Sawyer Rd. Waltham, MA; 2013. p. 02453. (UpToDate 2013).
    1. Bl AO. Fecal Microbiota Tranplantation. Curr Opin Gastroenterol. 2013;29(1):79–84. doi: 10.1097/MOG.0b013e32835a4b3e.
    1. Roses RE, Rombeau JL. Recent trends in the surgical management of inflammatory bowel disease. World J Gastroenterol. 2008;14:408–412. doi: 10.3748/wjg.14.408.
    1. Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, Schroeder TK. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120–127. doi: 10.1097/00000658-199508000-00003.
    1. Hahnloser D, Pemberton JH, Wolff BG, Larson DR, Crownhart BS, Dozois RR. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg. 2007;94:333–340. doi: 10.1002/bjs.5464.
    1. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53:1471–1478. doi: 10.1136/gut.2004.041616.
    1. Carter MJ, Lobo AJ, Travis SP. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl 5):V1–V16.
    1. Yamamoto T. Nutrition and diet in inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:216–221. doi: 10.1097/MOG.0b013e32835b9a40.
    1. Triggs CM, Munday K, Hu R, Fraser AG, Gearry RB, Barclay ML, Ferguson LR. Dietary factors in chronic inflammation: food tolerances and intolerances of a New Zealand Caucasian Crohn’s disease population. Mutat Res. 2010;690:123–138. doi: 10.1016/j.mrfmmm.2010.01.020.
    1. Pearson M, Teahon K, Levi AJ, Bjarnason I. Food intolerance and Crohn’s disease. Gut. 1993;34:783–787. doi: 10.1136/gut.34.6.783.
    1. Haas SV, Haas MP. Management of celiac disease. Lippincott, Philadelphia; 1951.
    1. Shivappa N, Steck SE, Hurley TG, Hussey JR, Hebert JR. Designing and developing a literature-derived, population-based dietary inflammatory index. Public Health Nutr. 2013;14:1–8.
    1. Cavicchia PP, Steck SE, Hurley TG, Hussey JR, Ma Y, Ockene IS, Hebert JR. A new dietary inflammatory index predicts interval changes in serum high-sensitivity C-reactive protein. J Nutr. 2009;139:2365–2372. doi: 10.3945/jn.109.114025.
    1. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–1845. doi: 10.1056/NEJM199406303302601.
    1. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–363. doi: 10.1016/j.cgh.2010.01.001.
    1. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut. 2004;53:1–4. doi: 10.1136/gut.53.1.1.
    1. O’Flaherty S, Saulnier DM, Pot B, Versalovic J. How can probiotics and prebiotics impact mucosal immunity? Gut Microbes. 2010;1:293–300. doi: 10.4161/gmic.1.5.12924.
    1. Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition (Burbank, Los Angeles County, Calif. 2009;25:520–525. doi: 10.1016/j.nut.2008.11.017.
    1. Bosscher D, Breynaert A, Pieters L, Hermans N. Food-based strategies to modulate the composition of the intestinal microbiota and their associated health effects. J Physiol Pharmacol. 2009;60(Suppl 6):5–11.
    1. Jia W, Whitehead RN, Griffiths L, Dawson C, Waring RH, Ramsden DB, Hunter JO, Cole JA. Is the abundance of Faecalibacterium prausnitzii relevant to Crohn’s disease? FEMS microbiology letters. 2010;310:138–144. doi: 10.1111/j.1574-6968.2010.02057.x.
    1. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16(18):2202–2222. doi: 10.3748/wjg.v16.i18.2202.
    1. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’Neil DA, Macfarlane GT. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242–249. doi: 10.1136/gut.2004.044834.
    1. Lorea Baroja M, Kirjavainen PV, Hekmat S, Reid G. Anti-inflammatory effects of probiotic yogurt in inflammatory bowel disease patients. Clin Exp Immunol. 2007;149:470–479. doi: 10.1111/j.1365-2249.2007.03434.x.
    1. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106:563–573. doi: 10.1038/ajg.2011.44.
    1. Guerreiro CS, Ferreira P, Tavares L, Santos PM, Neves M, Brito M, Cravo M. Fatty acids, IL6, and TNFalpha polymorphisms: an example of nutrigenetics in Crohn’s disease. Am J Gastroenterol. 2009;104:2241–2249. doi: 10.1038/ajg.2009.313.
    1. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther. 2011;5:185–210.
    1. Wall R, Ross RP, Fitzgerald GF, Stanton C. Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutrition reviews. 2010;68:280–289. doi: 10.1111/j.1753-4887.2010.00287.x.
    1. Guijarro LG, Mate J, Gisbert JP, Perez-Calle JL, Marin-Jimenez I, Arriaza E, Olleros T, Delgado M, Castillejo MS, Prieto-Merino D, Gonzalez Lara V, Pena AS. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. World J Gastroenterol. 2008;14:2851–2857. doi: 10.3748/wjg.14.2851.
    1. Choi JH, Chung KM, Park K. Psychosocial predictors of four health-promoting behaviors for cancer prevention using the stage of change of Transtheoretical Model. Psycho-Oncology. 2013;29(22):2253–2261.
    1. Podolsky DK. The future of IBD treatment. J Gastroenterol. 2003;38(Suppl 15):63–66.
    1. Sheil B, Shanahan F, O’Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr. 2007;137:819S–824S.
    1. Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Kohler H. Microbiota in pediatric inflammatory bowel disease. J Pediatr. 2010;157:240–244.e1. doi: 10.1016/j.jpeds.2010.02.046.
    1. Galland L. Rakel: Integrative Medicine. 2. Philadelphia: Saunders Elsevier; 2007.
    1. Paturi G, Mandimika T, Butts CA, Zhu S, Roy NC, McNabb WC, Ansell J. Influence of dietary blueberry and broccoli on cecal microbiota activity and colon morphology in mdr1a(-/-) mice, a model of inflammatory bowel diseases. Nutrition. 2012;28(3):324–330. doi: 10.1016/j.nut.2011.07.018.
    1. Osterman M. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47(3):212–221. doi: 10.1097/MCG.0b013e3182732ff5.
    1. Massironi S, Rossi R, Cavalcoli F, Della Valle S, Fraquell IM, Conte D. Nutritional deficiencies in inflammatory bowel disease: Therapeutic approaches. Clin Nutr. 2013;S0261-5614(13):00098–8.
    1. Donnellan C, Yann L, Lal S. Nutritional management of Crohn’s disease. Therap Adv Gastroenterol. 2013;6(3):231–242. doi: 10.1177/1756283X13477715.
    1. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology. 2010;139:1147–1155. doi: 10.1053/j.gastro.2010.06.070.
    1. Haas SV, Haas MP. The treatment of celiac disease with the specific carbohydrate diet; report on 191 additional cases. Am J Gastroenterol. 1955;23:344–360.
    1. Gottschall E. Breaking the Vicious Cycle: Intestinal Health through Diet. Baltimore, Ontario: Kirkton Press Ltd; 2004.
    1. Roberfroid M. Prebiotics: the concept revisited. J Nutr. 2007;137:830S–837S.
    1. Comino I, Real A, de Lorenzo L, Cornell H, Lopez-Casado MA, Barro F, Lorite P, Torres MI, Cebolla A, Sousa C. Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in coeliac disease. Gut. 2011;60:915–922. doi: 10.1136/gut.2010.225268.
    1. Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients. 2013;5:1869–1912. doi: 10.3390/nu5061869.
    1. Tilg H. Diet and intestinal immunity. N Engl J Med. 2012;366:181–183. doi: 10.1056/NEJMcibr1113158.
    1. Cohen AB, Lee D, Long MD, Kappelman MD, Martin CF, Sandler RS, Lewis JD. Dietary patterns and self-reported associations of diet with symptoms of inflammatory bowel disease. Dig Dis Sci. 2013;58:1322–1328. doi: 10.1007/s10620-012-2373-3.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться